This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
Age≥18 years
Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
Able to comprehend and speak English
Comorbid health condition that would interfere with study participation, as identified by the cancer care team
Parallel
PDAC-PATHWAYS
BehavioralA digital app for patients initiating neoadjuvant therapy for PDAC
Usual Care
Other interventionRoutine treatment
Feasibility: Enrollment rate
≥50% enrollment among consecutive eligible patients
Feasibility: intervention completion rate
≥50% completion of at least four app modules among those assigned to the intervention
Acceptability
≥70% of patients in the intervention arm reporting Client Satisfaction Questionnaire-8 scores at or above the midpoint score of 20 on a scale from 8-32 (higher scores indicate higher satisfaction)
Click on the lead sponsor to view all of their trials.
Massachusetts General Hospital
Lead sponsor
United States Department of Defense
Collaborator
